Researchers working alongside Australian diagnostics company Nutromics developed a minimally invasive patch that tracks the antibiotic in patients every five minutes.
SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that its software solution, Neurophet AQUA AD Plus, a comprehensive neuroimaging analysis solution for clinical evaluation related to Alzheimer’s disease, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Eyas Medical Imaging is currently scaling up operations with plans to commercialise the system in the US later this year.
Sonorous Neurovascular received FDA breakthrough device designation for its BosSTENT device intended to treat pulsatile tinnitus, the company announced on Thursday.
More than 2,000 known CFTR mutations have been identified worldwide. The type of mutation a patient carries can alter everything from how severe their symptoms are to what drugs will work for them.
A study led by researchers at UT Southwestern, published in the Journal of Clinical Investigation, suggests that a protein secreted by immune cells within these tumors causes them to grow even in the absence of estrogen.
Researchers at Washington University School of Medicine in St. Louis have developed a new tool to detect reconstruction-related infections early, before they cause symptoms.
Researchers from the Institute of Industrial Science, The University of Tokyo have used 3D-printing technology to improve the viral titer of microneedle array patches, resulting in effective immunogenicity and protection against infection in mice.
A research team led by Professor Víctor Yuste, from the Department of Biochemistry and Molecular Biology and the Institut de Neurociències de la UAB (INc-UAB), has designed and tested several bioadhesive patches that could be placed at the site where the tumor is removed during surgery, targeting any remaining cancer cells.
VIENNA, Feb. 5, 2026 /PRNewswire/ — P&F Products and Features GmbH, a global heart valve MedTech company focused on transcatheter solutions for structural heart disease, today announced it has received CE Mark certification under the European Union Medical Device Regulation (MDR) 2017/745 for its TricValve® Transcatheter Bicaval Valve System. The certification confirms TricValve’s compliance with the EU’s most stringent medical device regulatory requirements.